Immunome (IMNM) Depreciation & Amortization (CF) (2019 - 2026)
Immunome's (IMNM) quarterly Depreciation & Amortization (CF) came in at $603000.0 in Q1 2026, down 1.31% YoY from $611000.0 in Q1 2025, and down 9.05% on a QoQ basis from $663000.0 in Q4 2025.
Powered by 
Analysis
Immunome (IMNM) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $603000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 1.31% year-over-year to $603000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (up 21.32% YoY) and the FY2025 annual result came in at $2.5 million, up 56.25% from the prior year.
- Depreciation & Amortization (CF) declined to $603000.0 in Q1 2026, from $663000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $663000.0 in Q4 2025 to a low of $73000.0 in Q4 2022.
- A 5-year average of $329588.2 and a median of $194000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) tumbled 63.99% — and 2024, when it soared 443.56%.
- Tracing IMNM's Depreciation & Amortization (CF) over 5 years: stood at $73000.0 in 2022, then surged by 165.75% to $194000.0 in 2023, then jumped by 148.97% to $483000.0 in 2024, then surged by 37.27% to $663000.0 in 2025, then fell by 9.05% to $603000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $603000.0 (Q1 2026), $663000.0 (Q4 2025), and $589000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Immunome | 3.03 Bn | 2.51 Bn | - | 957,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 957,000.00 |
| Mar 31, 2026 | 603,000.00 |
| Dec 31, 2025 | 663,000.00 |
| Sep 30, 2025 | 589,000.00 |
| Jun 30, 2025 | 637,000.00 |
| Mar 31, 2025 | 611,000.00 |
| Dec 31, 2024 | 483,000.00 |
| Sep 30, 2024 | 411,000.00 |
| Jun 30, 2024 | 549,000.00 |
| Mar 31, 2024 | 157,000.00 |
| Dec 31, 2023 | 194,000.00 |
| Sep 30, 2023 | 111,000.00 |
| Jun 30, 2023 | 101,000.00 |
| Mar 31, 2023 | 94,000.00 |
| Dec 31, 2022 | 95,000.00 |
| Sep 30, 2022 | 103,000.00 |
| Jun 30, 2022 | 113,000.00 |
| Mar 31, 2022 | 111,000.00 |
| Dec 31, 2021 | 163,000.00 |
| Sep 30, 2021 | 286,000.00 |